Thousands of patients in Wales are turning to private providers for weight-loss injections as NHS waiting lists for specialist weight management services stretch as long as a decade in some areas.
Rising demand for treatments such as Mounjaro and Wegovy is exposing growing pressure on the National Health Service in Wales, where access remains limited compared with England.
NHS Waiting Lists Drive Patients to Private Treatment
Waiting times for specialist weight management services have increased sharply across multiple Welsh health boards, with some areas reporting delays of up to 10 years.
Figures show waiting lists have doubled or even quadrupled in certain regions over the past year, leaving many patients with little choice but to seek private treatment.
In one case, a patient facing a two-year wait opted to purchase injections privately, spending around £1,000 in six months to manage her condition.
Rising Demand Linked to Obesity and Health Conditions
The Welsh government estimates that around 186,000 people could be eligible for weight-loss medication, with more than 60% of adults classified as overweight or obese.
Conditions such as polycystic ovary syndrome (PCOS), sleep apnoea and high blood pressure are driving demand for treatment, as patients seek medical support to manage weight-related health risks.
Weight-loss injections work by suppressing appetite and regulating metabolism, helping patients feel fuller and reduce calorie intake.
Limited NHS Access Compared to England
Access to these treatments differs significantly across the UK. In England, weight-loss injections became available through GP surgeries in 2025, while in Wales they are restricted to specialist services or specific clinical cases.
To qualify in Wales, patients must meet strict criteria, including a high body mass index and completion of structured diet and exercise programmes before being considered for medication.
Health boards also face capacity limits, with some able to accept only a small number of new patients each year for injectable treatments.
Safety Concerns Over Private Use
Patients using private providers have raised concerns about the lack of medical supervision, with some relying on online pharmacies that offer limited clinical oversight.
Experts warn that prescription-only medicines should be used under the guidance of trained healthcare professionals to ensure safety and effectiveness.
The Welsh government has cautioned against purchasing medication from unregulated sources, highlighting risks associated with improper use and dosing.
Pressure Mounts on Welsh NHS Services
The surge in demand for weight management services has added to wider pressures on the Welsh NHS, which continues to face challenges related to funding, staffing and rising patient needs.
In some areas, routine referrals have been suspended due to long waiting lists, while urgent cases are prioritised for treatment.
Health officials say they are exploring new approaches to expand access, including potential changes to prescribing pathways and increased involvement of primary care services.
Political Debate Over Healthcare Access
The issue has sparked debate among political parties in Wales, with calls for reform of public health policy and greater investment in preventative care.
Critics argue that current systems are failing to meet demand, while others emphasise the need to promote healthier lifestyles alongside medical treatment.
Supporters of weight-loss medications say they could play a key role in reducing long-term healthcare costs by preventing obesity-related illnesses.
Growing Demand for Weight-Loss Treatments
The rise in demand for weight-loss injections reflects a broader global trend, as new medications offer more effective options for managing obesity.
Health systems worldwide are grappling with how to integrate these treatments into existing services, balancing cost, accessibility and clinical need.
In the UK, differences in policy between regions have created disparities in access, with patients in Wales facing longer waits and stricter eligibility criteria.
As demand continues to grow, policymakers face increasing pressure to expand access while ensuring treatments are delivered safely and sustainably.